WEBULL

Insider Buying: Aardvark Therapeutics CEO, Secretary & Director Bought US$101k Of Shares

Simply Wall St · 2d ago

Investors who take an interest in Aardvark Therapeutics, Inc. (NASDAQ:AARD) should definitely note that the CEO, Secretary & Director, Tien-Li Lee, recently paid US$14.49 per share to buy US$101k worth of the stock. Although the purchase is not a big one, by either a percentage standpoint or absolute value, it can be seen as a good sign.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Aardvark Therapeutics Insider Transactions Over The Last Year

In fact, the recent purchase by CEO, Secretary & Director Tien-Li Lee was not their only acquisition of Aardvark Therapeutics shares this year. Earlier in the year, they paid US$16.00 per share in a US$265k purchase. That means that an insider was happy to buy shares at above the current price of US$14.43. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.

In the last twelve months Aardvark Therapeutics insiders were buying shares, but not selling. Their average price was about US$12.06. It is certainly positive to see that insiders have invested their own money in the company. But we must note that the investments were made at well below today's share price. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

Check out our latest analysis for Aardvark Therapeutics

insider-trading-volume
NasdaqGS:AARD Insider Trading Volume December 15th 2025

There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership

Many investors like to check how much of a company is owned by insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 15% of Aardvark Therapeutics shares, worth about US$46m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

So What Does This Data Suggest About Aardvark Therapeutics Insiders?

It is good to see recent purchasing. We also take confidence from the longer term picture of insider transactions. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. Given that insiders also own a fair bit of Aardvark Therapeutics we think they are probably pretty confident of a bright future. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Our analysis shows 4 warning signs for Aardvark Therapeutics (2 make us uncomfortable!) and we strongly recommend you look at them before investing.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.